So snh p lc ln gan thn gia cc dng bo ch Dng bo ch quyt nh l trnh di chuyn ca hot cht v mc lm vic ca ni tng
In an ideal world, the need for such drugs would be reduced by population-based preventive strategies that reverse the upward shift in the population distribution of body mass index/body fat percentage. Unlike individual treatments, policy-level interventions need less personal effort and tend to reduce rather than increase health inequalities
A happy community of gut bugs is a well-moving community, even when taking medications that slow digestion
For instance, in the SURPASS-4 trial, where tirzepatide was compared with insulin glargine in patients with T2DM and a high cardiovascular risk, 15 mg of tirzepatide reduced the levels of TC, LDL-C, and TGs by 5.6%, 7.9%, and 22.5%, respectively, and increased the levels of HDL-C by 10.8%.5 In the SURPASS-5 trial, where tirzepatide was added to basal insulin treatment, tirzepatide also showed favorable effects on lipid profile parameters compared with placebo in patients with T2DM.6 Specifically, tirzepatide reduced the levels of TC, LDL-C, and TGs by 12.9%, 15.5%, and 24.9%, respectively, and increased the levels of HDL-C by 0.9%.6 In both trials, the effects of tirzepatide on lipid profile were dose-dependent, with greater improvements observed at higher doses and these improvements were sustained over the duration of the trials.5, 6 Table 1 summarizes the main findings of the SURPASS programs regarding the ability of tirzepatide to improve atherogenic dyslipidemia
